CIK 0001599298 · Large accelerated filer
Summit Therapeutics Inc.
Sign in to watch- Ticker
- SMMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 371979717
- Phone
- 305-203-2034
- Business address
- 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131
- Former names
- Summit Therapeutics plc, Summit Corp plc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-08 | Anand Bhaskar Chief Accounting Officer | Grant or award | +100,000 | 261,047 | ||
| 2026-06-12 | Zanganeh Mahkam Co-Chief Executive Officer | Purchase | +3,810,000 | $13.12 | $50.0M | 573,883,879 |
| 2026-06-12 | DUGGAN ROBERT W Co-Chief Executive Officer | Purchase | +3,810,000 | $13.12 | $50.0M | 573,883,879 |
| 2026-06-04 | Soni Manmeet Singh COO and CFO | Purchase | +25,000 | $14.46 | $362K | 3,098,603 |
| 2026-06-04 | Soni Manmeet Singh COO and CFO | Purchase | +25,000 | $14.43 | $361K | 3,123,603 |
| 2026-06-04 | Zanganeh Mahkam Co-Chief Executive Officer | Purchase | +100,000 | $14.60 | $1.5M | 25,824,474 |
| 2026-06-04 | DUGGAN ROBERT W Co-Chief Executive Officer | Purchase | +100,000 | $14.60 | $1.5M | 25,824,474 |
| 2026-01-08 | Anand Bhaskar Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2026-01-02 | Xia Yu Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-01-02 | Cesano Alessandra Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-01-02 | Cesano Alessandra Director | Grant or award · Stock Option (right to buy) | +3,219 | $8.76 | $28K | 3,219 |
| 2026-01-02 | Clark Kenneth A Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-01-02 | Clark Kenneth A Director | Grant or award · Stock Option (right to buy) | +17,796 | $8.76 | $156K | 17,796 |
| 2026-01-02 | Zanganeh Mahkam Co-Chief Executive Officer | Grant or award · Stock Option (right to buy) | +11,232 | $8.76 | $98K | 11,232 |
| 2026-01-02 | Booth Robert F. Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-01-02 | Booth Robert F. Director | Grant or award · Stock Option (right to buy) | +7,180 | $8.76 | $63K | 7,180 |
| 2026-01-02 | Huber Jeff Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-01-02 | Huber Jeff Director | Grant or award · Stock Option (right to buy) | +9,885 | $8.76 | $87K | 9,885 |
| 2026-01-02 | Ronaghi Mostafa Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-01-02 | DUGGAN ROBERT W Co-Chief Executive Officer | Grant or award · Stock Option (right to buy) | +11,232 | $8.76 | $98K | 11,232 |
Page 1 of 9 · 163 trades